EP Patent

EP2815748B1 — Compounds, formulations, and methods for treating or preventing rosacea

Assigned to Galderma Pharma SA · Expires 2020-08-05 · 6y expired

What this patent protects

Topical formulations are provided for treatment of rosacea incorporating compounds represented by the formulas below, including pharmaceutically acceptable salts thereof: wherein each of R 1 , R 2 , and R 3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R 4 …

USPTO Abstract

Topical formulations are provided for treatment of rosacea incorporating compounds represented by the formulas below, including pharmaceutically acceptable salts thereof: wherein each of R 1 , R 2 , and R 3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R 4 and R 5 is independently hydrogen, alkyl, or alkoxy; and each of R 6 and R 7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A 1 , A 3 , and A 4 is independently hydrogen or alkyl; and A 2 is independently hydrogen or hydroxy; and wherein each of B 1 , B 2 , and B 3 is independently hydrogen, hydroxy, or alkoxy; and each of B 4 and B 5 is independently hydrogen or substituted alkyl. In their use for the treatment of rosacea, the compounds are to be topically applied as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions.

Drugs covered by this patent

Patent Metadata

Patent number
EP2815748B1
Jurisdiction
EP
Classification
Expires
2020-08-05
Drug substance claim
No
Drug product claim
No
Assignee
Galderma Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.